Screener
Syndax Pharmaceuticals SNDX PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Collaboration receivable, net | 20,507 | 23,745 |
| Prepaid expenses and other current assets | 16,100 | 13,496 |
| Total current assets | 471,177 | 528,081 |
| Property and equipment, net | 177 | 181 |
| Right-of-use asset, net | 1,212 | 1,342 |
| Restricted cash | 102 | 102 |
| Total assets | $472,668 | $529,706 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's PP&E (net)?
- Syndax Pharmaceuticals (SNDX) reported PP&E (net) of $177K in Q1 2026.
- What is the long-term trend for Syndax Pharmaceuticals's PP&E (net)?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's PP&E (net) has grown at a -1.2% compound annual growth rate (CAGR), from $192K to $181K.
- What does PP&E (net) mean?
- Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.
Ask your AI about Syndax Pharmaceuticals's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude